# US 2016/0260511 A1 · Closed evaporation system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0260511 A1
- Document ID: US20160260511A1
- Status: Published application
- Kind: A1
- Application number: 15/027,633
- Filed: 2014-10-17
- Published: 2016-09-08
- Earliest claimed: 2013-10-18
- Assignees: Ge Healthcare Limited
- Applicants: Ge Healthcare Limited
- Inventors: Xavier Franci; Steve Lignon; Audrey Lange
- Web page: https://patentgrep.com/patent/US20160260511A1

## CPC

- G21F 9/08: by evaporation; by distillation
- B01D 1/30: Accessories for evaporators {; Constructional details thereof}
- B01J 19/0093: {Microreactors, e.g. miniaturised or microfabricated reactors (laboratory containers with capillary fluid transport in microfabricated channels or chambers B01L3/5027)}
- C07B 59/00: Introduction of isotopes of elements into organic compounds {; Labelled organic compounds per se}
- C07B 59/005: {Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids}
- C07C 227/40: Separation; Purification
- C07D 233/91: Nitro radicals
- C07H 19/06: Pyrimidine radicals
- C07J 1/007: {the substituent being an OH group free esterified or etherified}
- G21G 1/0005: {Isotope delivery systems (use of radioisotopes as tracers G21H5/02)}
- G21G 4/08: specially adapted for medical application (radiation therapy using radioactive sources A61N5/10)
- B01J 2219/00799: Cup-shaped
- B01J 2219/00873: Heat exchange
- B01J 2219/00885: Thin film heaters
- B01J 2219/009: Pulsating flow
- B01J 2219/00959: Flow
- B01J 2219/00963: Pressure
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07C 2601/04: with a four-membered ring
- G21F: PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR (radiation protection by pharmaceutical means A61K8/00, A61Q17/04; in cosmonautic vehicles B64G1/54; combined with a reactor G21C11/00; combined with X-ray tubes H01J35/16; combined with X-ray apparatus H05G1/02)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07J: STEROIDS (seco-steroids C07C)
- G21G: CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES (applications of radiation in general G21H5/00; handling particles, e.g. neutrons, or electromagnetic radiation not otherwise provided for G21K)

## Abstract

The present invention provides a system for evaporating a radioactive fluid, a method for the synthesis of a radiolabelled compound including this system, and a cassette for the synthesis of a radiolabelled compound comprising this system. The present invention provides advantages over known methods for evaporation of a radioactive fluid as it reduces drastically the amount of radioactive gaseous chemicals that are released in the hot cell. It is gentler and more secure compared to the known process and provides access to radiosyntheic processes that may not been acceptable for safety reasons related to release of volatile radioactive gases during evaporation. In addition, the process yields are higher because the radioactive volatiles are labelled intermediate species.

## Claims

### Claim 1

A system for evaporating a radioactive fluid wherein said system comprises:
(i) a fixed volume hot zone which comprises a fixed volume container and a heating means;
(ii) an expandable volume;
(iv) a 3-way valve which in a first position fluidly connects said fixed volume container and said an expandable volume and which in a second position fluidly connects said an expandable volume to waste.

### Claim 2 (depends on 1)

The system as defined in claim 1 wherein said fixed volume container is a reaction vessel.

### Claim 3 (depends on 1)

The system as defined in claim 1 wherein said heating means can heat said radioactive fluid to above its boiling point to reach the equilibrium gas/liquid phase of said radioactive fluid.

### Claim 4 (depends on 1)

The system as defined in claim 1 wherein said expandable volume is a syringe.

### Claim 5 (depends on 1)

A method for the synthesis of a radiolabelled compound wherein said method comprises:
(i) radiolabelling a protected precursor compound to obtain a protected radiolabelled compound;
(ii) deprotecting the protected radiolabelled compound obtained from radiolabelling step (i) to obtain said radiolabelled compound wherein said deprotection is effected using a hydrolysis medium; and,
(iii) evaporating the hydrolysis medium following deprotection step (ii) wherein said evaporating is carried out using the system as defined in claim 1.

### Claim 6 (depends on 5)

The method as defined in claim 5 wherein said radiolabelled compound is a radiopharmaceutical.

### Claim 7 (depends on 6)

The method as defined in claim 6 wherein said radiopharmaceutical is a diagnostic radiopharmaceutical.

### Claim 8 (depends on 7)

The method as defined in claim 7 wherein said diagnostic radiopharmaceutical is either a single photon emission tomography (SPECT) tracer or a positron emission tomography (PET) tracer.

### Claim 9 (depends on 8)

The method as defined in claim 8 wherein said diagnostic radiopharmaceutical is a PET tracer.

### Claim 10 (depends on 9)

The method as defined in claim 9 wherein said PET tracer comprises a 11C-labelled compound or an 18F-labelled compound.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A cassette for the synthesis of a radiopharmaceutical wherein said cassette comprises:
(i) a vessel containing a protected precursor compound;
(ii) means for eluting the vessel of step (i) with a suitable source of a radiolabel; and,
(iii) the system as defined in claim 1.

### Claim 15 (depends on 14)

The cassette as defined in claim 14 wherein said radiopharmaceutical is a diagnostic radiopharmaceutical.

### Claim 16 (depends on 15)

The cassette as defined in claim 15 wherein said diagnostic radiopharmaceutical is either a SPECT tracer or a PET tracer.

### Claim 17 (depends on 16)

The cassette as defined in claim 16 wherein said diagnostic radiopharmaceutical is a PET tracer.

### Claim 18 (depends on 17)

The cassette as defined in claim 17 wherein said PET tracer comprises a 11C-labelled compound or an 18F-labelled compound.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)